[{"orgOrder":0,"company":"Vaneltix Pharma","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","amount":"$6.7 million","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Enters into Strategic Partnership with Vaneltix for Treatment of Acute Pain in Interstitial Cystitis","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"Vaneltix Pharma","amount2":0.01,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Prefilled Syringe","sponsorNew":"Vaneltix Pharma \/ Hyloris","highestDevelopmentStatusID":"8","companyTruncated":"Vaneltix Pharma \/ Hyloris"},{"orgOrder":0,"company":"Vaneltix Pharma","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyloris Announces Enrolment of First Patient in a 4-Arm Clinical Trial of Alenura(TM)","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lidocaine","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"Vaneltix Pharma","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Vaneltix Pharma \/ Vaneltix Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Vaneltix Pharma \/ Vaneltix Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Vaneltix Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioJapan 2024
                          Not Confirmed
                          BioJapan 2024
                          Not Confirmed

                          Details : Alenura is a unique, combination product of alkalinised lidocaine and the glycosaminoglycan heparin. Alkalinised lidocaine penetrates the transitional epithelial cell layer and provides immediate pain relief.

                          Brand Name : Alenura

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 22, 2023

                          Lead Product(s) : Lidocaine,Heparin Sodium

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Recipient : Hyloris Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          BioJapan 2024
                          Not Confirmed
                          BioJapan 2024
                          Not Confirmed

                          Details : Under the terms of the agreement, Vaneltix will be responsible for the further development, manufacturing, regulatory affairs and commercialisation of AlenuraTM in collaboration with Hyloris.

                          Brand Name : Alenura

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 17, 2021

                          Lead Product(s) : Lidocaine,Heparin Sodium

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Sponsor : Hyloris Pharmaceuticals

                          Deal Size : $6.7 million

                          Deal Type : Collaboration

                          blank